Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The direct and indirect costs of the treatment of UC are high, and the quality of life of patients is reduced, especially during exacerbation of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies, including biologics, are currently used for the management of UC. However, many challenging issues exist, which sometimes lead to differences in practice between clinicians. Therefore, the Inflammatory Bowel Disease Study Group of the Korean Association for the Study of Intestinal Diseases established the first Korean guideline for the management of UC in 2012. This is an update of the first guideline. It was generally made by the adaptation of several foreign guidelines as was the first edition, and encompasses treatment of active colitis, maintenance of remission, and indication of surgery for UC. The specific recommendations are presented with the quality of evidence and classification of recommendations. (Korean J Gastroenterol 2017;69:1-28) Key Words: Colitis, ulcerative; Inflammatory bowel disease; Management; Guideline CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
최창환 등. 궤양성 대장염 치료 가이드라인 개정판
The Korean Journal of Gastroenterology We are moderately confident about the effect estimate: the true effect is most likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low
Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low
We have very little confidence in the effect estimate: the true effect is most likely to be substantially different from the estimate of the effect. Classification of recommendations Strong Most patients should receive the recommended course of action. Weak Clinicians should recognize that different choices would be appropriate for different patients and that they must help patients to arrive at a management decision consistent with their values and preferences. 
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The Korean Journal of Gastroenterology AZA의 권장 용량은 하루 2.0-2.5 mg/kg이며 6-MP의 경 우 1.0-1.5 mg/kg이다. 98, 199 
